DOCSLIB.ORG

Ether Lipid Generating Enzyme AGPS Alters the Balance of Structural and Signaling Lipids to Fuel Cancer Pathogenicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ether Lipid Generating Enzyme AGPS Alters the Balance of Structural and Signaling Lipids to Fuel Cancer Pathogenicity Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity Daniel I. Benjamina, Alyssa Cozzoa, Xiaodan Jib, Lindsay S. Robertsa, Sharon M. Louiea, Melinda M. Mulvihilla, Kunxin Luob, and Daniel K. Nomuraa,1 aProgram in Metabolic Biology, Department of Nutritional Sciences and Toxicology, and bDivision of Cell and Developmental Biology, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720 Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved July 29, 2013 (received for review June 7, 2013) Aberrant lipid metabolism is an established hallmark of cancer metabolism to favor generation of oncogenic signaling lipids, such cells. In particular, ether lipid levels have been shown to be as LPAe, lyosphosphatidic acid (LPA), and eicosanoids, which fuel elevated in tumors, but their specific function in cancer remains aggressive and tumorigenic features of cancer (12, 13, 16). Our elusive. We show here that the metabolic enzyme alkylglycer- studies thus reveal a heretofore unrecognized role of AGPS and onephosphate synthase (AGPS), a critical step in the synthesis of ether lipids in shifting the balance of fatty acid utilization from ether lipids, is up-regulated across multiple types of aggressive structural membrane lipids toward generation of oncogenic sig- human cancer cells and primary tumors. We demonstrate that naling lipids. ablation of AGPS in cancer cells results in reduced cell survival, Results and Discussion cancer aggressiveness, and tumor growth through altering the Cancer Cells Exhibit Heightened AGPS Expression and Ether Lipid balance of ether lipid, fatty acid, eicosanoid, and fatty acid– Metabolism. AGPS converts acyl-glycerone-3-phosphate into al- derived glycerophospholipid metabolism, resulting in an over- kyl-glycerone-3-phosphate, which is a requisite step in the gen- all reduction in the levels of several oncogenic signaling lipids. eration of all ether lipids. We hypothesized that cancer cells and Taken together, our results reveal that AGPS, in addition to main- tumors, which possess elevated levels of ether lipids, would have taining ether lipids, also controls cellular utilization of fatty acids, heightened AGPS expression. Consistent with this premise, we favoring the generation of signaling lipids necessary for promot- find that AGPS is highly expressed across aggressive breast ing the aggressive features of cancer. (231MFP), melanoma (C8161), and prostate cancer (PC3) cells compared with less aggressive cancer cells (MCF7, MUM2C, cancer metabolism | metabolomics | lipid signaling lysophosphatidic acid | and LNCaP, respectively) (Fig. 1A; Fig. S1A). We have reported eicosanoids that these aggressive cancer cells have heightened migratory, invasive, and tumorigenic properties compared with less ag- – ancer cells have fundamentally altered metabolism that gressive cells (17 19). We also show that AGPS expression is Cdrives their pathogenic features (1, 2). One hallmark of elevated two- to fourfold in Nottingham grade I (low-grade), II cancer cells is a heightened de novo lipogenic signature that (intermediate-grade), and III (high-grade) primary human breast tumors (Fig. 1B), as well as in estrogen receptor-positive/pro- serves as a critical foundation for generating lipids required for gesterone receptor-positive [ER(+)/PR(+)] and ER-negative/ cell proliferation (3, 4). For nearly half a century, it has also been PR-negative [ER(−)/PR(−)] breast tumors (Fig. 1C) compared known that cancer cells possess dramatically higher levels of – with normal breast tissue, indicating that AGPS expression may ether lipids compared with normal cells (5 8). Ether lipids have be heightened early in breast cancer development. Accordingly, we an alkyl or alkenyl chain on one or more carbons of the glycerol find that the expression of the commonly dysregulated transforming backbone bonded through an ether or vinyl linkage, rather than Harvey-Rat sarcoma oncogene (HRAS) (20) is heightened in the usual ester linkage. The physiological roles of ether lipids are not well understood, but they have been implicated in maintaining Significance physicochemical properties of cell membranes, such as membrane fluidity, membrane fusion events, and lipid raft microdomains fi (9, 10). Certain ether lipids, such as lysophosphatidic acid-ether Ether lipid levels are higher in tumors, but their speci c func- (LPAe) or platelet-activating factor-ether (PAFe), are signaling tion in cancer has remained unclear. We show here that the molecules that have been shown to possess bioactive and even metabolic enzyme alkylglyceronephosphate synthase (AGPS), oncogenic properties through binding specific receptors (11–15). a critical step in the synthesis of ether lipids, is up-regulated In the late 1960s, Snyder and Wood first reported that rodent across multiple types of aggressive human cancer cells and fi and human tumors possess significantly higher levels of ether lipids primary tumors. Inactivation of AGPS leads to signi cant relative to normal tissue. Over the ensuing decades, dramatic ele- impairments in cancer pathogenicity through not only lower- vations in ether lipid content have been confirmed for a wide range ing the levels of cellular ether lipids, but also by altering fatty of cancer cells and primary tumors from several tissues of origin and acid, eicosanoid, and glycerophospholipid metabolism, result- have been correlated with the proliferative capacity and tumorigenic ing in an overall reduction in the levels of several oncogenic potential of cancer cells (5–8). Nonetheless, whether elevated ether signaling lipids. lipids are causally linked, or merely associated with, cancer patho- Author contributions: D.I.B., L.S.R., S.M.L., K.L., and D.K.N. designed research; D.I.B., A.C., genicity has remained unclear. X.J., L.S.R., S.M.L., M.M.M., and D.K.N. performed research; D.I.B., K.L., and D.K.N. con- In this study, we show that inactivation of the critical enzyme tributed new reagents/analytic tools; D.I.B., A.C., X.J., L.S.R., S.M.L., M.M.M., and D.K.N. for ether lipid synthesis, alkylglycerone phosphate synthase (AGPS), analyzed data; and D.I.B., K.L., and D.K.N. wrote the paper. lowers ether lipid levels and impairs cancer pathogenicity, whereas The authors declare no conflict of interest. AGPS overexpression elevates ether lipid levels and increases This article is a PNAS Direct Submission. cancer cell motility, survival, and tumor growth. We also show that 1To whom correspondence should be addressed. E-mail: [email protected]. AGPS has a larger role beyond generating ether lipids to include This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. controlling fatty acid, eicosanoid, and acylglycerophospholipid 1073/pnas.1310894110/-/DCSupplemental. 14912–14917 | PNAS | September 10, 2013 | vol. 110 | no. 37 www.pnas.org/cgi/doi/10.1073/pnas.1310894110 Downloaded by guest on September 25, 2021 HRAS transformation of MCF10A mammary epithelial cells (21) A AGPS expression in B AGPS expression in C AGPS expression in human cancer cells primary human tumors primary human tumors induces up-regulation of AGPS expression (Fig. 1F). We thus show breast cancer melanoma that transformation of cells by HRAS is one regulatory route through 25 5 15 * 20 * * * 20 4 * 15 which cells may up-regulate AGPS expression. We also show that the ion 10 * 15 3 10 aggressive human breast 231MFP, melanoma C8161, and prostate 10 press 2 5 expression ex expression 5 5 1 expression PC3 cancer cells, as well as HRAS-transformed MCF10A cells, 0 0 0 0 possess significantly higher ether lipid levels compared with their MCF7 C8161 less aggressive MCF7, MUM2C, and LNCaP counterparts, or grade 3 231MFP MUM2C grade 1/2 G B–F ER(-)/PR(-) ER(+)/PR(+) MCF10A control cells (Fig. 1 ; Fig. S1 ; Dataset S1). Height- normal tissue normal tissue breast tumorsbreast tumors breast tumorsbreast tumors ened lipid species include phosphatidic acid-ether (PAe), LPAe, D correlation between E F HRAS and AGPS expression HRAS expression in AGPS expression upon phosphatidyl inositol-ether (PIe), phosphatidylcholine-ether (PCe), in primary breast tumors human cancer cells RAS transformation lysophosphatidylcholine-ether (LPCe), phosphatidylserine-ether HRAS expression primary breast tumors breast cancer melanoma AGPS expression (PSe), phosphatidylglycerol-ether (PGe), lysophopshatidylglycerol- in primary breast tumors 4 4 5 * ether(LPGe)lipids,andplasmalogen ether lipids, such as 15 15 r = 0.59 * * * 4 G p<0.0001 3 3 phosphatidylethanolamine-plasmalogen (PEp) (Fig. 1 ; Fig. S1 10 * 10 3 2 2 B–F fi 2 ). We annotate ether lipids in this study by the speci c ether (e) pression 5 5 x expression expression e 1 1 expression 1 or plasmalogen (p) species and alkyl chain length and type (carbon 0 HRAS expression 0 0 0 0 number:degree of unsaturation—e.g., C16:0e is a palmityl-ether 0 5 10 15 G B–F AGPS expression MCF7 C8161 linkage with no unsaturation) in Fig. 1 and Fig. S1 . Our results MUM2C grade 3 231MFP MCF10A grade 1/2 HRAS-10A show that AGPS expression and ether lipid levels are heightened in normal tissue breast tumorsbreast tumors multiple types of aggressive human cancer cells and upon RAS ether lipid levels in human cancer cells G transformation and that AGPS expression is increased in primary breast cancer melanoma RAS transformation breast tumors. AGPS Is a Critical Enzyme in Cancer Pathogenicity. We next sought to MCF7 231MFP MUM2C C8161 MCF10AHRAS-10A C16:0e/18:1 PAe C16:0e/18:1 PAe C16:0e/18:1 PAe determine the extent to which AGPS was necessary for maintaining C16:0e/20:4 PAe C16:0e/20:4 PAe C16:0e/20:4 PAe C16:0e LPAe C16:0e LPAe C16:0e LPAe the pathogenic features of cancer cells. We generated two inde- C16:0e/18:1 PIe C16:0e/18:1 PIe C16:0e/18:1 PCe C16:0e/20:4 PIe C16:0e/20:4 PIe C16:0e/20:4 PCe pendent stable short hairpin knockdown lines of AGPS (shAGPS-1 C16:0e/18:1 PCe C16:0e/18:1 PCe C16:0e LPCe and shAGPS-2) with greater than 90% knockdown in breast C16:0e/20:4 PCe C16:0e/20:4 PCe C16:0e/18:1 PEe C16:0e LPCe C16:0e LPCe C18:0e/C18:1 PEe 231MFP and melanoma C8161 cancer cells (Fig.
Load more

Recommended publications
  • Synthesis of Lysophospholipids
    Molecules 2010, 15, 1354-1377; doi:10.3390/molecules15031354 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Synthesis of Lysophospholipids Paola D’Arrigo 1,2,* and Stefano Servi 1,2 1 Dipartimento di Chimica, Materiali ed Ingegneria Chimica “Giulio Natta”, Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy 2 Centro Interuniversitario di Ricerca in Biotecnologie Proteiche "The Protein Factory", Politecnico di Milano and Università degli Studi dell'Insubria, Via Mancinelli 7, 20131 Milano, Italy * Author to whom correspondence should be addressed; E-Mail: paola.d’[email protected]. Received: 17 February 2010; in revised form: 4 March 2010 / Accepted: 5 March 2010 / Published: 8 March 2010 Abstract: New synthetic methods for the preparation of biologically active phospholipids and lysophospholipids (LPLs) are very important in solving problems of membrane–chemistry and biochemistry. Traditionally considered just as second-messenger molecules regulating intracellular signalling pathways, LPLs have recently shown to be involved in many physiological and pathological processes such as inflammation, reproduction, angiogenesis, tumorogenesis, atherosclerosis and nervous system regulation. Elucidation of the mechanistic details involved in the enzymological, cell-biological and membrane-biophysical roles of LPLs relies obviously on the availability of structurally diverse compounds. A variety of chemical and enzymatic routes have been reported in the literature for the synthesis of LPLs: the enzymatic transformation of natural glycerophospholipids (GPLs) using regiospecific enzymes such as phospholipases A1 (PLA1), A2 (PLA2) phospholipase D (PLD) and different lipases, the coupling of enzymatic processes with chemical transformations, the complete chemical synthesis of LPLs starting from glycerol or derivatives. In this review, chemo- enzymatic procedures leading to 1- and 2-LPLs will be described.
    [Show full text]
  • Chemistry and Physics of Lipids Effects of Ether Vs. Ester Linkage On
    Chemistry and Physics of Lipids 160 (2009) 33–44 Contents lists available at ScienceDirect Chemistry and Physics of Lipids journal homepage: www.elsevier.com/locate/chemphyslip Effects of ether vs. ester linkage on lipid bilayer structure and water permeability S. Deren Guler a, D. Dipon Ghosh b, Jianjun Pan a, John C. Mathai c, Mark L. Zeidel c, John F. Nagle a,b, Stephanie Tristram-Nagle a,∗ a Department of Physics, Carnegie Mellon University, Pittsburgh, PA 15213, USA b Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA c Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Cambridge, MA 02139, USA article info abstract Article history: The structure and water permeability of bilayers composed of the ether-linked lipid, dihexadecylphos- Received 29 January 2009 phatidylcholine (DHPC), were studied and compared with the ester-linked lipid, dipalmitoylphosphadit- Received in revised form 29 March 2009 dylcholine (DPPC). Wide angle X-ray scattering on oriented bilayers in the fluid phase indicate that the Accepted 26 April 2009 area per lipid A is slightly larger for DHPC than for DPPC. Low angle X-ray scattering yields A = 65.1 Å2 for Available online 3 May 2009 ◦ −13 DHPC at 48 C. LAXS data provide the bending modulus, KC = 4.2 × 10 erg, and the Hamaker parame- ter H =7.2× 10−14 erg for the van der Waals attractive interaction between neighboring bilayers. For the Keywords: low temperature phases with ordered hydrocarbon chains, we confirm the transition from a tilted L␤ Ether lipid ◦ gel phase to an untilted, interdigitated L␤I phase as the sample hydrates at 20 C.
    [Show full text]
  • The Gut Microbiome Modulates Gut–Brain Axis Glycerophospholipid
    Molecular Psychiatry (2021) 26:2380–2392 https://doi.org/10.1038/s41380-020-0744-2 ARTICLE The gut microbiome modulates gut–brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression 1,2,3,4 5 1,2,3 4 1,2,3 1,2,3 Peng Zheng ● Jing Wu ● Hanping Zhang ● Seth W. Perry ● Bangmin Yin ● Xunmin Tan ● 1,2,3 6 1,2,3 1,2,3 5 4 4 Tingjia Chai ● Weiwei Liang ● Yu Huang ● Yifan Li ● Jiajia Duan ● Ma-Li Wong ● Julio Licinio ● Peng Xie1,2,3 Received: 27 December 2019 / Revised: 9 April 2020 / Accepted: 20 April 2020 / Published online: 6 May 2020 © The Author(s), under exclusive licence to Springer Nature Limited 2020 Abstract Emerging research demonstrates that microbiota-gut–brain (MGB) axis changes are associated with depression onset, but the mechanisms underlying this observation remain largely unknown. The gut microbiome of nonhuman primates is highly similar to that of humans, and some subordinate monkeys naturally display depressive-like behaviors, making them an ideal model for studying these phenomena. Here, we characterized microbial composition and function, and gut–brain metabolic 1234567890();,: 1234567890();,: signatures, in female cynomolgus macaque (Macaca fascicularis) displaying naturally occurring depressive-like behaviors. We found that both microbial and metabolic signatures of depressive-like macaques were significantly different from those of controls. The depressive-like monkeys had characteristic disturbances of the phylum Firmicutes. In addition, the depressive-like macaques were characterized by changes in three microbial and four metabolic weighted gene correlation network analysis (WGCNA) clusters of the MGB axis, which were consistently enriched in fatty acyl, sphingolipid, and glycerophospholipid metabolism.
    [Show full text]
  • Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS As Anti-Cancer Agents † # ‡ # § # † § Valentina Piano, , Daniel I
    Articles pubs.acs.org/acschemicalbiology Discovery of Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anti-Cancer Agents † # ‡ # § # † § Valentina Piano, , Daniel I. Benjamin, , Sergio Valente, , Simone Nenci, Biagina Marrocco, § ∥ ⊥ ‡ † Antonello Mai, , Alessandro Aliverti, Daniel K. Nomura,*, and Andrea Mattevi*, † Department of Biology and Biotechnology, University of Pavia, via Ferrata 9, 27100 Pavia, Italy ‡ Program in Metabolic Biology, Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California 94720, United States § Department of Drug Chemistry and Technologies, University “La Sapienza”, P. le A. Moro 5, Roma 00185, Italy ∥ Pasteur Institute, Cenci Bolognetti Foundation, P.le A. Moro 5, Roma 00185, Italy ⊥ Department of Biosciences, University of Milano, Via Festa del Perdono, 7, 20122 Milano, Italy *S Supporting Information ABSTRACT: Dysregulated ether lipid metabolism is an important hallmark of cancer cells. Previous studies have reported that lowering ether lipid levels by genetic ablation of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS) lowers key structural and oncogenic ether lipid levels and alters fatty acid, glycerophospholipid, and eicosanoid metabolism to impair cancer pathogenicity, indicating that AGPS may be a potential therapeutic target for cancer. In this study, we have performed a small-molecule screen to identify candidate AGPS inhibitors. We have identified several lead AGPS inhibitors and have structurally characterized their interactions with the enzyme and show that these inhibitors bind to distinct portions of the active site. We further show that the lead AGPS inhibitor 1a selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration. We provide here the first report of in situ-active pharmacological tools for inhibiting AGPS, which may provide chemical scaffolds for future AGPS inhibitor development for cancer therapy.
    [Show full text]
  • Phosphatidic Acid: Biosynthesis, Pharmacokinetics, Mechanisms of Action and Effect on Strength and Body Composition in Resistance-Trained Individuals Peter Bond
    Bond Nutrition & Metabolism (2017) 14:12 DOI 10.1186/s12986-017-0166-6 REVIEW Open Access Phosphatidic acid: biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals Peter Bond Abstract The mechanistic target of rapamycin complex 1 (mTORC1) has received much attention in the field of exercise physiology as a master regulator of skeletal muscle hypertrophy. The multiprotein complex is regulated by various signals such as growth factors, energy status, amino acids and mechanical stimuli. Importantly, the glycerophospholipid phosphatidic acid (PA) appears to play an important role in mTORC1 activation by mechanical stimulation. PA has been shown to modulate mTOR activity by direct binding to its FKBP12-rapamycin binding domain. Additionally, it has been suggested that exogenous PA activates mTORC1 via extracellular conversion to lysophosphatidic acid and subsequent binding to endothelial differentiation gene receptors on the cell surface. Recent trials have therefore evaluated the effects of PA supplementation in resistance-trained individuals on strength and body composition. As research in this field is rapidly evolving, this review attempts to provide a comprehensive overview of its biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals. Keywords: Phosphatidic acid, mTORC1, Muscle hypertrophy Background complex and functions as a serine/threonine protein kin- Skeletal muscle mass comprises roughly half of our body ase belonging to the phosphatidylinositol-3 kinase mass and is essential for locomotion, heat production (PI3K)-related kinase (PIKK) superfamily [7]. mTORC1 during periods of cold stress and overall metabolism [1]. acts as a signal integrator of various environmental cues Skeletal muscle mass can be increased by mechanical and controls protein synthesis, specifically the process of loading such as a resistance exercise program [2].
    [Show full text]
  • Hot Topics in Neural Membrane Lipidology
    A.A. Farooqui Hot Topics in Neural Membrane Lipidology ▶ Focuses exclusively on lipid mediators and neurological disorders Not only do glycerophospholipid, sphingolipid, and cholesterol-derived lipid mediators facilitate the transfer of messages from one cell to another, they also facilitate communication among subcellular organelles. Hot Topics in Neural Membrane Lipidology provides readers with a cutting-edge, comprehensive review of these lipid mediators, their roles and association with neurological disorders, and the future direction of research on the topic. This monograph provides readers with critical data and is particularly accessible to neuroscience graduate students, teachers, and researchers. It can be used as a supplemental text for a range of neuroscience courses. Clinicians and pharmacologists will find this book useful for understanding molecular aspects of lipid mediators in acute neural trauma like stroke, spinal cord trauma, head injury, and neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and Huntington disease. 2009, XXIV, 408 p. 62 illus. About the Author: Printed book Akhlaq A. Farooqui is a leader in the field of brain phospholipases A2, bioactive ether lipid metabolism, and glutamate-mediated neurotoxicity. He has discovered the stimulation of Hardcover plasmalogen-selective phospholipase A2 activity in brains from patients with Alzheimer ▶ 199,99 € | £179.99 | $249.99 disease, and published cutting edge research on the generation and identification of ▶ *213,99 € (D) | 219,99 € (A) | CHF 236.00 glycerophospholipid, sphingolipid, and cholesterol-derived lipid mediators in kainic acid neurotoxicity. Dr. Farooqui has authored three monographs: Glycerophospholipids eBook in Brain: Phospholipase A2 in Neurological Disorders (2007); Neurochemical Aspects of Excitotoxicity (2008); and Metabolism and Functions of Bioactive Ether Lipids in Brain Available from your bookstore or (2008).
    [Show full text]
  • The Ether Lipid-Deficient Mouse: Tracking Down Plasmalogen Functions ⁎ Karin Gorgas A, Andre Teigler B, Dorde Komljenovic A, Wilhelm W
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1763 (2006) 1511–1526 www.elsevier.com/locate/bbamcr Review The ether lipid-deficient mouse: Tracking down plasmalogen functions ⁎ Karin Gorgas a, Andre Teigler b, Dorde Komljenovic a, Wilhelm W. Just b, a Institut für Anatomie und Zellbiologie, Abteilung Medizinische Zellbiologie, Im Neuenheimer Feld 307, D-69120 Heidelberg, Germany b Biochemie-Zentrum der Universität Heidelberg (BZH), Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany Received 29 June 2006; received in revised form 15 August 2006; accepted 23 August 2006 Available online 30 August 2006 Abstract Chemical and physico-chemical properties as well as physiological functions of major mammalian ether-linked glycerolipids, including plasmalogens were reviewed. Their chemical structures were described and their effect on membrane fluidity and membrane fusion discussed. The recent generation of mouse models with ether lipid deficiency offered the possibility to study ether lipid and particularly plasmalogen functions in vivo. Ether lipid-deficient mice revealed severe phenotypic alterations, including arrest of spermatogenesis, development of cataract and defects in central nervous system myelination. In several cell culture systems lack of plasmalogens impaired intracellular cholesterol distribution affecting plasma membrane functions and structural changes of ER and Golgi cisternae. Based on these phenotypic anomalies that were accurately described conclusions were drawn on putative functions of plasmalogens. These functions were related to cell–cell or cell–extracellular matrix interactions, formation of lipid raft microdomains and intracellular cholesterol homeostasis. There are several human disorders, such as Zellweger syndrome, rhizomelic chondrodysplasia punctata, Alzheimer’s disease, Down syndrome, and Niemann–Pick type C disease that are distinguished by altered tissue plasmalogen concentrations.
    [Show full text]
  • Control of Free Arachidonic Acid Levels by Phospholipases A2 And
    Control of Free Arachidonic Acid Levels by Phospholipases A2 and Lysophospholipid Acyltransferases Gema Pérez-Chacón, Alma M. Astudillo, David Balgoma, María A. Balboa, and Jesús Balsinde* Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC), 47003 Valladolid, Spain, and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08036 Barcelona, Spain *Corresponding author. Phone, +34-983-423-062; Fax, +34-983-184-800; e-mail: [email protected] Keywords: Arachidonic Acid; Phospholipase A2; Free fatty acid; Eicosanoids; Acyltransferase; Phospholipid Remodeling. Running Title: Control of Arachidonic Acid Levels 1 Abstract Arachidonic acid (AA) and its oxygenated derivatives, collectively known as the eicosanoids, are key mediators of a wide variety of physiological and pathophysiological states. AA, obtained from the diet or synthesized from linoleic acid, is rapidly incorporated into cellular phospholipids by the concerted action of arachidonoyl-CoA synthetase and lysophospholipid acyl transferases. Under the appropriate conditions, AA is liberated from its phospholipid storage sites by the action of one or various phospholipase A2 enzymes. Thus, cellular availability of AA, and hence the amount of eicosanoids produced, depends on an exquisite balance between phospholipid reacylation and hydrolysis reactions. This review focus on the enzyme families that are involved in these reactions in resting and stimulated cells. Abbreviations AA, arachidonic
    [Show full text]
  • Bioactive Ether Lipids: Primordial Modulators of Cellular Signaling
    H OH metabolites OH Review Bioactive Ether Lipids: Primordial Modulators of Cellular Signaling Nikhil Rangholia 1,† , Tina M. Leisner 2 and Stephen P. Holly 1,* 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC 27506, USA; [email protected] 2 Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected] † Current address: Frontage Laboratories Inc., 75 E. Uwchian Ave, STE 100, Exton, PA 19341, USA. Abstract: The primacy of lipids as essential components of cellular membranes is conserved across taxonomic domains. In addition to this crucial role as a semi-permeable barrier, lipids are also increasingly recognized as important signaling molecules with diverse functional mechanisms ranging from cell surface receptor binding to the intracellular regulation of enzymatic cascades. In this review, we focus on ether lipids, an ancient family of lipids having ether-linked structures that chemically differ from their more prevalent acyl relatives. In particular, we examine ether lipid biosynthesis in the peroxisome of mammalian cells, the roles of selected glycerolipids and glycerophospholipids in signal transduction in both prokaryotes and eukaryotes, and finally, the potential therapeutic contributions of synthetic ether lipids to the treatment of cancer. Keywords: ether lipid; alkylglycerol; signaling; signal transduction; glycerolipid; glycerophospho- lipid; apoptosis; platelet; cancer 1. Introduction Citation: Rangholia, N.; Leisner, Much like many other types of organic molecules, lipids are essential for life—even T.M.; Holly, S.P.
    [Show full text]
  • Antiproliferative Effect of Two Novel Palmitoylcarnitine Analogs
    Eur. J. Biochem. 266, 855±864 (1999) q FEBS 1999 Anti-proliferative effect of two novel palmitoyl-carnitine analogs, selective inhibitors of protein kinase C conventional isoenzymes Tea Garcia-Huidobro, Enrique Valenzuela, Andrea V. Leisewitz, Jaime Valderrama and Miguel Bronfman Departamento de BiologõÂa Celular y Molecular, Facultad de Ciencias BioloÂgicas y Facultad de QuõÂmica, P. Universidad CatoÂlica de Chile, Santiago, Chile Previous studies have shown that palmitoyl-carnitine is an anti-proliferative agent and a protein kinase C inhibitor. Two new palmitoyl-carnitine analogs were synthesized by replacing the ester bond with a metabolically more stable ether bond. An LD50 value in the nm range was found in anti-proliferative assays using HL-60 cells and was dependent on the alkyl-chain length. The inhibitory action of these water-soluble compounds on protein kinase C in vitro was greatly increased with respect to palmitoyl-carnitine and was dependent on the length of the alkyl chain. Its effect was mediated by an increase in the enzyme's requirement for phosphatidylserine. Inhibition of the in situ phosphorylation of a physiological platelet protein kinase C substrate and of phorbol ester-induced differentiation of HL-60 cells was also observed. Finally, to test for isoenzyme selectivity, several human recombinant protein kinase C isoforms were used. Only the Ca2+-dependent classic protein kinase Cs (a, bI, bII and g) were inhibited by these compounds, yet the activities of casein kinase I, Ca2+/calmodulin-dependent kinase and cAMP-dependent protein kinase were unaffected. Thus, these novel inhibitors appear to be both protein kinase C and isozyme selective.
    [Show full text]
  • The TMEM189 Gene Encodes Plasmanylethanolamine Desaturase Which Introduces the Characteristic Vinyl Ether Double Bond Into Plasmalogens
    The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens Ernst R. Wernera,1, Markus A. Kellerb, Sabrina Sailera, Katharina Lacknera, Jakob Kochb, Martin Hermannc, Stefan Coassind, Georg Golderera, Gabriele Werner-Felmayera, Raphael A. Zoellere, Nicolas Hulof, Johannes Bergerg, and Katrin Watschingera,1 aInstitute of Biological Chemistry, Biocenter, Medical University of Innsbruck, A-6020 Innsbruck, Austria; bInstitute of Human Genetics, Medical University of Innsbruck, A-6020 Innsbruck, Austria; cUniversity Clinic for Anesthesiology and General Intensive Care Medicine, Medical University of Innsbruck, A-6020 Innsbruck, Austria; dInstitute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, A-6020 Innsbruck, Austria; eDepartment of Physiology and Biophysics, Boston University School of Medicine, Boston, MA 02118; fInstitute of Genetics and Genomics, University of Geneva, 1211 Geneva 4, Switzerland; and gDepartment of Pathobiology of the Nervous System, Medical University of Vienna, 1090 Vienna, Austria Edited by Benjamin F. Cravatt, Scripps Research Institute, La Jolla, CA, and approved February 26, 2020 (received for review October 7, 2019) A significant fraction of the glycerophospholipids in the human body severe clinical outcomes, including impaired neural development, is composed of plasmalogens, particularly in the brain, cardiac, and bone deformation, and premature death. The initial peroxisomal immune cell membranes. A decline in these lipids has been observed steps of human plasmalogen biosynthesis have been well charac- in such diseases as Alzheimer’s and chronic obstructive pulmonary terized to require the genes GNPAT (11, 12), AGPS (13), and disease. Plasmalogens contain a characteristic 1-O-alk-1′-enyl ether DHRS7B (14). Further downstream steps occurring in the en- (vinyl ether) double bond that confers special biophysical, biochemi- doplasmic reticulum are less well understood, however.
    [Show full text]
  • Phosphatidylcholine Treatment to Induce Lipolysis
    Journal Innoventions PhosphatidylcholineBlackwell Publishing Inc treatment to induce lipolysis Franz Hasengschwandtner Therapy-Clinic Center, Bad Leonfelden, Austria Summary The medicine Lipostabil N® has been in widespread use in Europe since 2002 by doctors working in the field of esthetics to achieve a reduction in the volume of smaller fat deposits by means of injections into the subcutaneous fatty tissue. The lipases released from the adipocytes by means of phosphatidylcholine produce a local breakdown of fat that is then discharged over the liver and metabolized via beta- oxidation. The medicine has been authorized for intravenous use in the prophylaxis and therapy of fat embolisms and liver diseases. Keywords: detergents, lecithins, lipolysis, phosphatidylcholine her lower eye pads by injecting phosphatidylcholine History under her eyes.2 In Europe, further study of the medica- Phosphatidylcholine was first isolated in Odessa, Ukraine ment started in 2001, and the first treatments were made some 50 years ago. This was followed by further research by the author in late 2002. In 2003 “Network Lipolysis” in Germany and Russia. It has been marketed by Sanofi- was founded in Germany by Ulrich Bunzek and Dirk Aventis for over 30 years and, at present, the substance Brandl and with this started the European investigation phosphatidylcholine is registered in 53 countries. Its main of the scientific background of this new esthetic therapy. application nowadays lies in the intravenous treatment Phosphatidylcholine makes up the largest choline and prevention of fat embolisms in polytraumatized (lecithin) reservoir in the body and is found in bile. It patients in the treatment of metabolic disorders and as a facilitates the emulsification of fat into the tiniest particles liver-protecting substance.
    [Show full text]